Business Segments

9 Months Ended

Sep. 30, 2011

Segment Reporting [Abstract]

Segment Reporting Disclosure [Text Block]

Note 7. Business Segments

The Company maintains two active business segments: BioTherapeutics and Vaccines/BioDefense. Each segment includes an element of overhead costs specifically associated with its operations, with its corporate shared services group responsible for support functions generic to both operating segments.

	Three Months Ended September 30,
	2011			2010
Revenue
Vaccines/BioDefense	$	581,943		$	781,894
BioTherapeutics		5,213,919			78,623
Total	$	5,795,862		$	860,517
Income (Loss) from Operations
Vaccines/BioDefense	$	5,869		$	(23,785	)
BioTherapeutics		2,684,937			(1,237,725	)
Corporate		(487,343	)		(477,005	)
Total	$	2,203,463		$	(1,738,515	)
Amortization and Depreciation Expense
Vaccines/BioDefense	$	11,247		$	20,656
BioTherapeutics		47,791			28,349
Corporate		559			486
Total	$	59,597		$	49,491
Interest Income, Net
Corporate	$	1,411		$	4,775
Stock-Based Compensation
Vaccines/BioDefense	$	16,998		$	19,498
BioTherapeutics		60,487			134,908
Corporate		63,668			186,638
Total	$	141,153		$	341,044

	Nine Months Ended September 30,
	2011			2010
Revenue
Vaccines/BioDefense	$	1,453,558		$	1,383,788
BioTherapeutics		5,556,129			257,167
Total	$	7,009,687		$	1,640,955
Income (Loss) Loss from Operations
Vaccines/BioDefense (1)	$	5,921		$	(748,942	)
BioTherapeutics		(359,792	)		(3,616,978	)
Corporate		(1,098,302	)		(1,089,492	)
Total	$	(1,452,173	)	$	(5,455,412	)
Amortization and Depreciation Expense
Vaccines/BioDefense	$	31,119		$	57,731
BioTherapeutics		132,282			76,068
Corporate		1,641			1,471
Total	$	165,042		$	135,270
Interest Income, Net
Corporate	$	5,319		$	8,120
Stock-Based Compensation
Vaccines/ BioDefense	$	53,830		$	45,379
BioTherapeutics		346,995			189,177
Corporate		128,963			229,353
Total	$	529,788		$	463,909

(1)   During the nine months ended September 30, 2010, the Company incurred $378,501 in a one-time patent write off cost related to its anticipated return of the botulinum toxin vaccine license and abandonment of related patents. This cost is reflected in research and development expense in the consolidated statement of operations.

	As of September 30,  2011		As of December 31, 2010
Identifiable Assets
Vaccines/BioDefense	$	591,040	$	480,995
BioTherapeutics		936,546		927,973
Corporate		7,387,516		7,859,579
Total	$	8,915,102	$	9,268,547